Sulbactam-based therapy for Acinetobacter baumannii infection: A systematic review and meta-analysis

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages 389-394

  Chu, Haiqing ^a   Zhao, Lan ^a   Wang, Minggui ^b   Liu, Yang ^b   Gui, Tao ^a   Zhang, Jingbo ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Acinetobacter baumannii; Infection; Meta analysis; Sulbactam; Systematic review

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM; CEFOPERAZONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COLISTIN; DOXYCYCLINE; MINOCYCLINE; PENICILLIN DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER INFECTION; ANTIMICROBIAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; INFECTION; META-ANALYSIS; SULBACTAM; SYSTEMATIC REVIEW;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; SULBACTAM; TREATMENT OUTCOME;

EID: 84880941177     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.10.029     Document Type: Article

References (21)

1. Garnacho-Montero J., Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010, 23:332-339.
2. Karageorgopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
3. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
4. Gaynes R., Edwards J.R., National Nosocomial Infections Surveillance System Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005, 41:848-854.
5. Paul M., Weinberger M., Siegman-Igra Y., et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 2005, 60:256-260.
6. Vila J., Pachon J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 2012, 13:2319-2336.
7. Halstead D.C., Abid J., Dowzicky M.J. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance. Trial J Infect 2007, 55:49-57.
8. Lode H.M. Rational antibiotic therapy and the position of ampicillin/sulbactam. Int J Antimicrob Agents 2008, 32:10-28.
9. Williams J.D. Beta-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 1997, 24:494-497.
10. Corbella X., Ariza J., Ardanuy C., et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998, 42:793-802.
11. Rafailidis P.I., Ioannidou E.N., Falagas M.E. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs 2007, 67:1829-1849.
12. Betrosian A.P., Douzinas E.E. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol 2009, 5:1099-1112.
13. Kempf M., Djouhri-Bouktab L., Brunel J.M., Raoult D., Rolain J.M. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012, 39:180-181.
14. Mellon G., Clec'h C., Picard B., Cohen Y., Jaureguy F. Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother 2012, 18:958-960.
15. Pei G., Mao Y., Sun Y. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii. Microb Drug Resist 2012, 18:574-577.
16. Santimaleeworagun W., Wongpoowarak P., Chayakul P., Pattharachayakul S., Tansakul P., Garey K.W. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 2011, 42:890-900.
17. Wells G.A., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2012, Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [accessed 02.08.12].
18. Lee C.M., Lim H.K., Liu C.P., Tseng H.K. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005, 37:195-199.
19. Choi J.Y., Kim C.O., Park Y.S., et al. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. Yonsei Med J 2006, 47:63-69.
20. Betrosian A.P., Frantzeskaki F., Xanthaki A., Douzinas E.E. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008, 56:432-436.
21. Chan J.D., Graves J.A., Dellit T.H. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010, 25:343-348.